Source: Monash IVF Group
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Following new health orders in Victoria, Monash IVF Group (MVF) says non-urgent surgery protocols will disrupt some IVF procedures in Melbourne and other major centres
  • The group says patients who plan to commence a stimulated cycle after January 6, 2022 will need to undertake a clinical assessment first to determine urgency
  • Stimulated cycles whereby patients have commenced their drug regime prior to January 6, 2022 will continue along with some other procedures
  • The health order came into effect on January 12 and lasts until April 12, 2022 with the company unsure whether it will impact IVF services for the full three-month period
  • Shares have been down 1 per cent trading at $1.02

Following new health orders in Victoria, Monash IVF Group (MVF) has said non-urgent surgery protocols will disrupt some IVF procedures in Melbourne and other major centres.

These new health orders are designed to assist Victorian hospitals respond to rising coronavirus cases by alleviating pressure on the state’s health system.

The group says patients who plan to commence a stimulated cycle after January 6, 2022 will need to undertake a clinical assessment first to determine urgency.

Stimulated cycles whereby patients have commenced their drug regime prior to January 6, 2022 will continue.

Frozen embryo transfer, intrauterine insemination and medical preservation procedures are also continuing during the health order period.

The health order came into effect on January 12 and lasts until April 12, 2022 with the company unsure whether it will impact IVF services for the full three-month period.

The group expects the order will create pent-up treatment demand which will be services within three to four months following resumption of services.

Shares in Monash IVF Group were down 1 per cent trading at $1.02 each at 1:39 pm AEDT.

MVF by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece